Generex Biotechnology (Generex Biotechnology) Valuation Rank

View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Generex Biotechnology Valuation Rank Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Generex Biotechnology (Generex Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Valuation Rank

Comparable Companies

RBSH MRPI BOM:531207 HSTC PPCB NUGX BOM:506365 CDXI IMUN RSPI

Traded in Other Exchanges

N/A

Address

10102 USA Today Way, Miramar, FL, USA, 33025

Website

https://www.generex.com

Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.

Executives

Prioletti Mark Joseph Se	director	1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr	director	450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines	other: Consultant	11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher	officer: EVP General Counsel &Secretary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee	director	201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr.	director	33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao	officer: CFO & Treasurer	531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr.	director, officer: SVP of Research & Drug Develop	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman	director	10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti	director	10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro	director, officer: SVP & Chief Investment Officer	10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard	officer: Chief Operating Officer	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows	officer: Chief Financial Officer	33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von	director, officer: President of Subsidiary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt	director	555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1